Rezaei Niloufar, Tamaskani Zahedi Sina, Hajihashemi Parisa, Nasiri-Dehsorkhi Hamid, Zamani Arefeh, Ebrahimi Amrollah, Adibi Peyman, Armstrong David
Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Behavioral Sciences Research Center, Student research committee, Department of Health Psychology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Eat Disord. 2025 Jun 26:1-19. doi: 10.1080/10640266.2025.2519904.
Avoidant/restrictive food intake disorder (ARFID) is characterized by restrictive and avoidant feeding and eating behaviors not linked to body weight or shape concerns, potentially exacerbated by disorders of gut-brain interaction (DGBI). This scoping review was conducted to systematically map the literature on ARFID and DGBI to determine the prevalence of ARFID in DGBI, the prevalence of DGBI in ARFID patients, and the association between these disorders. Online databases, including PubMed, Scopus, and Web of Science were systematically reviewed from 2013 to April 2025. Studies that reported the prevalence of ARFID in DGBI groups, the prevalence of DGBI in ARFID individuals, and examined the association between ARFID and DGBI were included. Out of 4,085 screened sources, nine studies met the inclusion criteria. The prevalence of ARFID in patients with DGBI ranged from 13.2% to 40%. Individuals with ARFID showed a higher risk for DGBI and its symptoms compared to controls. This review summarized the prevalence of ARFID in DGBI patients, and the association between these disorders. Limitations include small sample sizes and inconsistencies in diagnostic scales. Larger-scale research is needed to clarify the association, along with improved assessment tools for accurate diagnosis of ARFID and DGBI.
回避/限制性食物摄入障碍(ARFID)的特征是存在限制性和回避性的进食行为,这些行为与对体重或体型的担忧无关,可能因肠脑交互障碍(DGBI)而加剧。本范围综述旨在系统梳理关于ARFID和DGBI的文献,以确定DGBI中ARFID的患病率、ARFID患者中DGBI的患病率以及这些障碍之间的关联。对包括PubMed、Scopus和Web of Science在内的在线数据库进行了系统检索,检索时间范围为2013年至2025年4月。纳入了报告DGBI组中ARFID患病率、ARFID个体中DGBI患病率并研究ARFID与DGBI之间关联的研究。在4085篇筛选出的文献中,有9项研究符合纳入标准。DGBI患者中ARFID的患病率在13.2%至40%之间。与对照组相比,ARFID个体出现DGBI及其症状的风险更高。本综述总结了DGBI患者中ARFID的患病率以及这些障碍之间的关联。局限性包括样本量小和诊断量表不一致。需要开展更大规模的研究来阐明这种关联,同时需要改进评估工具以准确诊断ARFID和DGBI。